What is the estimated price of filgotinib in 2025

As a highly selective JAK1 inhibitor, the biggest benefit of filgotinib is that it can suppress the inflammatory response while keeping the risk of side effects relatively controllable. Compared with non-selective JAK inhibitors, filgotinib has less interference with hematopoiesis and immune defense systems, giving it significant advantages in the long-term management of chronic inflammatory diseases. For people with rheumatoid arthritis, it not only reduces joint swelling, pain and morning stiffness, but also improves quality of life and daily functional abilities. In patients with ulcerative colitis, filgotinib can reduce the risk of disease recurrence by reducing intestinal mucosal inflammation, improving the rate of remission and maintaining remission time.

The oral delivery method of the drug is also a significant advantage. Figotinib can achieve ideal blood concentrations when taken orally once a day, simplifying the complexity of long-term chronic disease management and improving patient compliance. Its targeted effect gives clinicians more flexibility in formulating individualized treatment plans and can provide reliable alternatives when traditional DMARDs or biological agents are ineffective.

In terms of price, the original drug of filgotinib has not yet been launched in China, so it is not covered by domestic medical insurance, and the price paid by patients has not yet been determined. The European version of the original drug that has been launched in overseas markets has a specification of 200 mg × 30 tablets per box, and the price is about more than 10,000 yuan. In order to reduce the economic burden, some overseas generic drugs have also been put on the market. For example, the Laos pharmaceutical factory produces 100 mg × 30 tablets per box, and the price is about more than 900 yuan (slightly fluctuating due to the exchange rate). Its drug ingredients are basically the same as the original drugs. Through these channels, patients can obtain relatively cost-controllable treatment options when purchasing overseas or across borders.

In general, filgotinib has become an emerging drug for the treatment of chronic autoimmune diseases due to its high selectivityJAK1 inhibition, good oral convenience, and efficacy in rheumatoid arthritis and ulcerative colitis.

Reference materials:https://go.drugbank.com/drugs/DB14845